The OARSI Clinical Trials Symposium occurred on Wednesday, October 20, 2021. Nearly 200 attendees learned from OARSI members and individuals from the FDA in a debate that continued previous discussions among OARSI, the FDA, and the Arthritis Foundation. If you missed the symposium or would like to view it again, you can view the recording.
A special thank you to our sponsors: Biosplice, Nordic Bioscience, and Pfizer | Lilly.
Published every Friday, the OARSI Weekly Briefing the single resource you need to stay up to date with OARSI & World Congress news, membership announcements, and happenings within the OARSI & OA community.
January 14, 2022 - Current Briefing
By popular demand, the OARSI Live webinar series is back. The next OARSI Live will be held on Wednesday, January 19 at 9:00 am ET.
This webinar will discuss a recently published genome-wide association study, “Deciphering osteoarthritis genetics across 826,690 individuals from 9 populations” (DOI: 10.1016/j.cell.2021.07.038). The study represents the largest GWAS to date, identifying new genetic variants in both weight-bearing (knee, hip, and spine) and non-weight-bearing joints (hand, finger, and thumb). We will discuss methods, possible clinical implications, and future directions. Bring your questions and thoughts for an engaging discussion!
By Various
~The Pre-Competitive Consortium for Osteoarthritis, an initiative of the Osteoarthritis Research Society International, submitted a White Paper...
Tags: White Paper, Serious Disease, FDA
By Multiple Authors
For the first time, OARSI has developed treatment guidelines tailored to different types of patients with osteoarthritis (OA) of the knee. These...
Tags: Patient Summary, Guidelines, Knee Osteoarthritis
